SCHEMBL19670171

SCHEMBL19670171

C/N=C/c1cccc(-c2ccc3c(n2)N(C(=O)Nc2cncc(F)c2)[C@H]2CCN3C2)c1

nearest known ligand 0.32

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PIM2 Q9P1W9 3/20 0.32
▸ DYRK1A Q13627 3/20 0.32
▸ GSK3B P49841 2/20 0.32
▸ HRH3 Q9Y5N1 2/20 0.31
▸ ALDH1A1 P00352 1/20 0.31
▸ MAPT P10636 1/20 0.31
▸ SMN1; SMN2 Q16637 1/20 0.31
▸ ABL1 P00519 3/20 0.30
▸ CLK2 P49760 1/20 0.30
▸ MEN1 O00255 1/20 0.30
▸ NPC1 O15118 1/20 0.30
▸ HSP90AA1 P07900 1/20 0.30
▸ RAB9A P51151 1/20 0.30
▸ KMT2A Q03164 1/20 0.30
▸ PAX8 Q06710 1/20 0.30
▸ CNR1 P21554 1/20 0.30
▸ HTR2C P28335 1/20 0.30
▸ HTR2B P41595 1/20 0.30
▸ LPL P06858 1/20 0.30
▸ LIPC P11150 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19670387 0.89 HTR2C (0.38) PIM2ALDH1A1MAPTHTR2CHTR2B
SCHEMBL19699058 0.88 USP2 (0.35) DYRK1AGSK3BHRH3MAPTMEN1
SCHEMBL19365346 0.87 SCD (0.37) ALDH1A1ABL1LPLLIPCLIPG
SCHEMBL19706030 0.87 SCD (0.37) ALDH1A1ABL1LPLLIPCLIPG
SCHEMBL19670592 0.86 CLK2 (0.36) DYRK1AGSK3BHRH3ALDH1A1MAPT
SCHEMBL17618432 0.86 CNR1 (0.36) MAPTSMN1; SMN2MEN1RAB9AKMT2A
SCHEMBL17618507 0.86 CNR1 (0.36) MAPTSMN1; SMN2MEN1RAB9AKMT2A
SCHEMBL19670176 0.86 CNR1 (0.36) MAPTSMN1; SMN2MEN1RAB9AKMT2A
SCHEMBL19670154 0.86 PIM2 (0.34) PIM2DYRK1A
SCHEMBL19706065 0.85 RPS6KA3 (0.38) HRH3ALDH1A1MAPTSMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10590135-B2 Substituted bridged urea analogs as sirtuin modulators GLAXOSMITHKLINE LLC (US) 2020-03-17 — — US disclosed
US-20170355697-A1 SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC 2017-12-14 — — US disclosed
US-9834558-B2 Substituted bridged urea analogs as sirtuin modulators GLAXOSMITHKLINE LLC (US) 2017-12-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170355697-A1 SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS SIRT1, SIRT3, SIRT2 PIM2 3242/4885DYRK1A 2623/4885GSK3B 1728/4885
US-10590135-B2 Substituted bridged urea analogs as sirtuin modulators SIRT1, SIRT3, SIRT2 PIM2 3242/4885DYRK1A 2623/4885GSK3B 1728/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback